Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890424595> ?p ?o ?g. }
- W2890424595 endingPage "1329" @default.
- W2890424595 startingPage "1321" @default.
- W2890424595 abstract "BackgroundThe achievement of glycaemic control remains challenging for patients with type 1 diabetes. We assessed the effectiveness of day-and-night hybrid closed-loop insulin delivery compared with sensor-augmented pump therapy in people with suboptimally controlled type 1 diabetes aged 6 years and older.MethodsIn this open-label, multicentre, multinational, single-period, parallel randomised controlled trial, participants were recruited from diabetes outpatient clinics at four hospitals in the UK and two centres in the USA. We randomly assigned participants with type 1 diabetes aged 6 years and older treated with insulin pump and with suboptimal glycaemic control (glycated haemoglobin [HbA1c] 7·5–10·0%) to receive either hybrid closed-loop therapy or sensor-augmented pump therapy over 12 weeks of free living. Training on study insulin pump and continuous glucose monitoring took place over a 4-week run-in period. Eligible subjects were randomly assigned using central randomisation software. Allocation to the two study groups was unblinded, and randomisation was stratified within centre by low (<8·5%) or high (≥8·5%) HbA1c. The primary endpoint was the proportion of time that glucose concentration was within the target range of 3·9–10·0 mmol/L at 12 weeks post randomisation. Analyses of primary outcome and safety measures were done in all randomised patients. The trial is registered with ClinicalTrials.gov, number NCT02523131, and is closed to accrual.FindingsFrom May 12, 2016, to Nov 17, 2017, 114 individuals were screened, and 86 eligible patients were randomly assigned to receive hybrid closed-loop therapy (n=46) or sensor-augmented pump therapy (n=40; control group). The proportion of time that glucose concentration was within the target range was significantly higher in the closed-loop group (65%, SD 8) compared with the control group (54%, SD 9; mean difference in change 10·8 percentage points, 95% CI 8·2 to 13·5; p<0·0001). In the closed-loop group, HbA1c was reduced from a screening value of 8·3% (SD 0·6) to 8·0% (SD 0·6) after the 4-week run-in, and to 7·4% (SD 0·6) after the 12-week intervention period. In the control group, the HbA1c values were 8·2% (SD 0·5) at screening, 7·8% (SD 0·6) after run-in, and 7·7% (SD 0·5) after intervention; reductions in HbA1c percentages were significantly greater in the closed-loop group compared with the control group (mean difference in change 0·36%, 95% CI 0·19 to 0·53; p<0·0001). The time spent with glucose concentrations below 3·9 mmol/L (mean difference in change −0·83 percentage points, −1·40 to −0·16; p=0·0013) and above 10·0 mmol/L (mean difference in change −10·3 percentage points, −13·2 to −7·5; p<0·0001) was shorter in the closed-loop group than the control group. The coefficient of variation of sensor-measured glucose was not different between interventions (mean difference in change −0·4%, 95% CI −1·4% to 0·7%; p=0·50). Similarly, total daily insulin dose was not different (mean difference in change 0·031 U/kg per day, 95% CI −0·005 to 0·067; p=0·09) and bodyweight did not differ (mean difference in change 0·68 kg, 95% CI −0·34 to 1·69; p=0·19). No severe hypoglycaemia occurred. One diabetic ketoacidosis occurred in the closed-loop group due to infusion set failure. Two participants in each study group had significant hyperglycaemia, and there were 13 other adverse events in the closed-loop group and three in the control group.InterpretationHybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes.FundingJDRF, NIHR, and Wellcome Trust. The achievement of glycaemic control remains challenging for patients with type 1 diabetes. We assessed the effectiveness of day-and-night hybrid closed-loop insulin delivery compared with sensor-augmented pump therapy in people with suboptimally controlled type 1 diabetes aged 6 years and older. In this open-label, multicentre, multinational, single-period, parallel randomised controlled trial, participants were recruited from diabetes outpatient clinics at four hospitals in the UK and two centres in the USA. We randomly assigned participants with type 1 diabetes aged 6 years and older treated with insulin pump and with suboptimal glycaemic control (glycated haemoglobin [HbA1c] 7·5–10·0%) to receive either hybrid closed-loop therapy or sensor-augmented pump therapy over 12 weeks of free living. Training on study insulin pump and continuous glucose monitoring took place over a 4-week run-in period. Eligible subjects were randomly assigned using central randomisation software. Allocation to the two study groups was unblinded, and randomisation was stratified within centre by low (<8·5%) or high (≥8·5%) HbA1c. The primary endpoint was the proportion of time that glucose concentration was within the target range of 3·9–10·0 mmol/L at 12 weeks post randomisation. Analyses of primary outcome and safety measures were done in all randomised patients. The trial is registered with ClinicalTrials.gov, number NCT02523131, and is closed to accrual. From May 12, 2016, to Nov 17, 2017, 114 individuals were screened, and 86 eligible patients were randomly assigned to receive hybrid closed-loop therapy (n=46) or sensor-augmented pump therapy (n=40; control group). The proportion of time that glucose concentration was within the target range was significantly higher in the closed-loop group (65%, SD 8) compared with the control group (54%, SD 9; mean difference in change 10·8 percentage points, 95% CI 8·2 to 13·5; p<0·0001). In the closed-loop group, HbA1c was reduced from a screening value of 8·3% (SD 0·6) to 8·0% (SD 0·6) after the 4-week run-in, and to 7·4% (SD 0·6) after the 12-week intervention period. In the control group, the HbA1c values were 8·2% (SD 0·5) at screening, 7·8% (SD 0·6) after run-in, and 7·7% (SD 0·5) after intervention; reductions in HbA1c percentages were significantly greater in the closed-loop group compared with the control group (mean difference in change 0·36%, 95% CI 0·19 to 0·53; p<0·0001). The time spent with glucose concentrations below 3·9 mmol/L (mean difference in change −0·83 percentage points, −1·40 to −0·16; p=0·0013) and above 10·0 mmol/L (mean difference in change −10·3 percentage points, −13·2 to −7·5; p<0·0001) was shorter in the closed-loop group than the control group. The coefficient of variation of sensor-measured glucose was not different between interventions (mean difference in change −0·4%, 95% CI −1·4% to 0·7%; p=0·50). Similarly, total daily insulin dose was not different (mean difference in change 0·031 U/kg per day, 95% CI −0·005 to 0·067; p=0·09) and bodyweight did not differ (mean difference in change 0·68 kg, 95% CI −0·34 to 1·69; p=0·19). No severe hypoglycaemia occurred. One diabetic ketoacidosis occurred in the closed-loop group due to infusion set failure. Two participants in each study group had significant hyperglycaemia, and there were 13 other adverse events in the closed-loop group and three in the control group. Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes." @default.
- W2890424595 created "2018-09-27" @default.
- W2890424595 creator A5002226918 @default.
- W2890424595 creator A5002572291 @default.
- W2890424595 creator A5003979070 @default.
- W2890424595 creator A5004314992 @default.
- W2890424595 creator A5005498736 @default.
- W2890424595 creator A5005971350 @default.
- W2890424595 creator A5007594312 @default.
- W2890424595 creator A5012170772 @default.
- W2890424595 creator A5012940714 @default.
- W2890424595 creator A5012999559 @default.
- W2890424595 creator A5013980025 @default.
- W2890424595 creator A5014136673 @default.
- W2890424595 creator A5014542620 @default.
- W2890424595 creator A5014910048 @default.
- W2890424595 creator A5015050089 @default.
- W2890424595 creator A5015976716 @default.
- W2890424595 creator A5016379733 @default.
- W2890424595 creator A5017090852 @default.
- W2890424595 creator A5017748880 @default.
- W2890424595 creator A5018911748 @default.
- W2890424595 creator A5018978061 @default.
- W2890424595 creator A5019359424 @default.
- W2890424595 creator A5019732007 @default.
- W2890424595 creator A5023259818 @default.
- W2890424595 creator A5023812575 @default.
- W2890424595 creator A5023814642 @default.
- W2890424595 creator A5027935204 @default.
- W2890424595 creator A5028783235 @default.
- W2890424595 creator A5029112610 @default.
- W2890424595 creator A5029279856 @default.
- W2890424595 creator A5034096266 @default.
- W2890424595 creator A5034950348 @default.
- W2890424595 creator A5035916164 @default.
- W2890424595 creator A5036585419 @default.
- W2890424595 creator A5037954936 @default.
- W2890424595 creator A5041346301 @default.
- W2890424595 creator A5041700802 @default.
- W2890424595 creator A5046189462 @default.
- W2890424595 creator A5046837679 @default.
- W2890424595 creator A5047879571 @default.
- W2890424595 creator A5048565116 @default.
- W2890424595 creator A5050996976 @default.
- W2890424595 creator A5054090255 @default.
- W2890424595 creator A5054394741 @default.
- W2890424595 creator A5055377420 @default.
- W2890424595 creator A5055494325 @default.
- W2890424595 creator A5057490763 @default.
- W2890424595 creator A5058859252 @default.
- W2890424595 creator A5058966489 @default.
- W2890424595 creator A5059027086 @default.
- W2890424595 creator A5059687616 @default.
- W2890424595 creator A5062092441 @default.
- W2890424595 creator A5066623761 @default.
- W2890424595 creator A5066949583 @default.
- W2890424595 creator A5068506640 @default.
- W2890424595 creator A5069460986 @default.
- W2890424595 creator A5070342484 @default.
- W2890424595 creator A5072290866 @default.
- W2890424595 creator A5074486986 @default.
- W2890424595 creator A5079496521 @default.
- W2890424595 creator A5080270275 @default.
- W2890424595 creator A5081405643 @default.
- W2890424595 creator A5082279445 @default.
- W2890424595 creator A5083093599 @default.
- W2890424595 creator A5084909252 @default.
- W2890424595 creator A5085323390 @default.
- W2890424595 creator A5086602765 @default.
- W2890424595 creator A5091162738 @default.
- W2890424595 date "2018-10-01" @default.
- W2890424595 modified "2023-10-09" @default.
- W2890424595 title "Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial" @default.
- W2890424595 cites W1982250075 @default.
- W2890424595 cites W2075361652 @default.
- W2890424595 cites W2098570086 @default.
- W2890424595 cites W2102877966 @default.
- W2890424595 cites W2148347826 @default.
- W2890424595 cites W2181256817 @default.
- W2890424595 cites W2332531077 @default.
- W2890424595 cites W2469701129 @default.
- W2890424595 cites W2470196169 @default.
- W2890424595 cites W2520448718 @default.
- W2890424595 cites W2528859617 @default.
- W2890424595 cites W2562987464 @default.
- W2890424595 cites W2577069570 @default.
- W2890424595 cites W2579875664 @default.
- W2890424595 cites W2587843318 @default.
- W2890424595 cites W2597871801 @default.
- W2890424595 cites W2615150331 @default.
- W2890424595 cites W2730137350 @default.
- W2890424595 cites W2799357239 @default.
- W2890424595 cites W2802855656 @default.
- W2890424595 cites W4250647894 @default.
- W2890424595 doi "https://doi.org/10.1016/s0140-6736(18)31947-0" @default.
- W2890424595 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6182127" @default.
- W2890424595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30292578" @default.
- W2890424595 hasPublicationYear "2018" @default.